GLP-1 Microdosing and Gastroparesis: Does a Low Dose Slow Stomach Emptying, and Does It Last?

Slower stomach emptying is part of how GLP-1 medicines work. Food leaves the stomach later, glucose enters the blood more gradually, and fullness lasts longer. The same effect explains much of the nausea, reflux and bloating people report in the first weeks.

This article draws on two physiology trials, two semaglutide trials that measured emptying directly, a meta-analysis of 15 emptying studies, two large cohort studies that counted gastroparesis diagnoses, and two meta-analyses of what turns up in the stomach at endoscopy and anaesthesia. One limit runs through all of it: every study used standard doses. No trial has measured gastric emptying or gastroparesis risk at the sub-label doses used in microdosing protocols.

Does GLP-1 microdosing cause gastroparesis?

There is no direct evidence that GLP-1 microdosing causes gastroparesis, because no study has looked at microdoses. What the research does show is that standard GLP-1 doses slow gastric emptying, that this slowing usually lessens over time, and that a formal gastroparesis diagnosis on these drugs is rare.

It helps to separate two ideas. Delayed gastric emptying is a measurement: food takes longer to leave the stomach. Gastroparesis is a clinical diagnosis, made when emptying is delayed and symptoms persist without a physical blockage. A GLP-1 medicine can produce the first in almost everyone who takes it without producing the second. Our guide to reflux and sulfur burps on a GLP-1 microdose covers the everyday symptoms that come from a slower stomach.

How much do GLP-1 medicines slow the stomach?

GLP-1 medicines slow the stomach by roughly half an hour on the most direct test. Hiramoto and colleagues pooled 15 studies in a 2024 meta-analysis in the American Journal of Gastroenterology. In the 5 studies (247 people) that used gastric emptying scintigraphy, the mean half-emptying time was 138.4 minutes on a GLP-1 medicine against 95.0 minutes on placebo.

The pooled difference was 36.0 minutes, with a confidence interval of 17.0 to 55.0 minutes. The 10 studies (411 people) that used the acetaminophen absorption test, which mostly reflects liquid emptying, found no significant delay. On meta-regression, the type of GLP-1 drug and the length of treatment did not change the result. The authors concluded that a delay of about 36 minutes is of limited size compared with standard pre-procedure fasting periods.

Does the stomach slowdown from a GLP-1 wear off?

The GLP-1 stomach slowdown usually wears off at least partly, a process called tachyphylaxis. Nauck and colleagues showed it in a 2011 study in Diabetes. Nine healthy volunteers received an 8.5 hour GLP-1 infusion and two liquid meals 4 hours apart. GLP-1 slowed emptying significantly more after the first meal than after the second, and the authors traced the fading to reduced vagal nerve signalling.

Long-acting drugs behave the same way over weeks. Urva and colleagues, in a 2020 Lilly-sponsored study in Diabetes, Obesity and Metabolism, found that a single tirzepatide dose delayed emptying at 5 mg or more in people with type 2 diabetes and 4.5 mg or more in people without it. The effect diminished after multiple doses in healthy participants. In people with type 2 diabetes on 5/5/10/10 or 5/5/10/15 mg escalation schedules, a residual delay was still present. In obese mice, the effect was gone after 2 weeks.

A 2024 review by Jalleh and colleagues in the Journal of Clinical Endocrinology and Metabolism lists tachyphylaxis with prolonged treatment as a key feature. It also notes that GLP-1 receptor activation has only a limited effect on emptying in people whose stomachs already empty slowly before treatment.

If emptying returns to normal, why does appetite stay lower?

Appetite stays lower because GLP-1 medicines act on appetite through more than the stomach. Friedrichsen and colleagues randomized 72 adults with obesity to semaglutide 2.4 mg or placebo for 20 weeks in a Novo Nordisk-sponsored trial published in Diabetes, Obesity and Metabolism in 2021. At week 20 the authors found no evidence of delayed gastric emptying, assessed indirectly by acetaminophen absorption.

Even so, people on semaglutide ate 35% less at a free-choice lunch, 1736 kJ against 2676 kJ, and lost 9.9% of body weight against 0.4% on placebo. The main emptying measure rose 8%, a difference that was no longer significant once week 20 body weight was taken into account.

A smaller crossover trial by Hjerpsted and colleagues in Diabetes, Obesity and Metabolism (2018) adds detail. In 30 people with obesity on semaglutide escalated to 1.0 mg for 12 weeks, first-hour emptying was delayed (treatment ratio 0.73), while overall emptying across 5 hours did not differ from placebo. The stomach may hold food a little longer early in a meal and still finish on time.

How common is gastroparesis on semaglutide?

Gastroparesis on semaglutide is uncommon but more frequent than on some other weight treatments. Aneke-Nash and colleagues studied 55,460 adults with obesity and no type 2 diabetes in US MarketScan claims from 2018 to 2022, published in BMJ Open Gastroenterology in 2025. Of them, 36,990 (66.7%) used semaglutide.

The rate was 6.5 per 1000 person-years on semaglutide, 2.1 on bupropion-naltrexone and 1.1 after sleeve gastrectomy. After adjustment, semaglutide users had a higher risk than bupropion-naltrexone users (hazard ratio 3.33) and sleeve gastrectomy patients (hazard ratio 6.14). The authors still described the side effect as rare. Claims data capture diagnosis codes, not confirmed emptying tests, so some codes may reflect ordinary drug-related nausea labelled as gastroparesis.

Is tirzepatide harder on the stomach than semaglutide?

Tirzepatide does not appear harder on the stomach than semaglutide in the largest head-to-head cohort so far. Crisafulli and colleagues, writing in the Annals of Internal Medicine (2026), compared adults with type 2 diabetes who started dulaglutide, semaglutide or tirzepatide between 2019 and 2024. The outcome was a composite of severe GI events: pancreatitis, biliary disease, bowel obstruction, gastroparesis and severe constipation.

The hazard ratios were 0.96 for semaglutide versus dulaglutide (65,238 matched pairs), 0.96 for tirzepatide versus dulaglutide (20,893 pairs) and 1.07 for tirzepatide versus semaglutide (46,620 pairs). Every confidence interval crossed 1.0. For a closer look at how the two drugs compare at their lowest doses, see our piece on microdose semaglutide vs tirzepatide.

What does a slower stomach mean before endoscopy or anaesthesia?

A slower stomach means food is more likely to still be there after a normal fast, though pooled data do not show more aspiration. Baig and colleagues pooled 23 observational studies with 262,018 patients in Gastrointestinal Endoscopy (2025). GLP-1 users had higher odds of residual gastric contents (odds ratio 4.54) and of a procedure being stopped early (also 4.54), with no significant difference in aspiration pneumonia (odds ratio 0.96).

Elkin and colleagues reached the same pattern in Anaesthesia (2025). Across 18 studies with 165,522 patients, GLP-1 exposure was linked to residual gastric contents despite appropriate fasting (odds ratio 5.96). Across 9 studies with 185,414 patients, it was not linked to pulmonary aspiration (odds ratio 1.04, confidence interval 0.87 to 1.25). In 5 studies with 1706 patients, withholding at least one dose before the procedure was associated with lower odds of residual contents (odds ratio 0.51), on very low certainty evidence.

The practical point is to tell the procedure team about any GLP-1 use, including a microdose. Our article on GLP-1 microdosing before surgery and anaesthesia covers how fasting advice is changing.

Does a smaller dose mean less stomach slowing?

A smaller dose plausibly means less stomach slowing, but the evidence for microdoses specifically does not exist yet. The lowest single doses shown to delay emptying in the tirzepatide study were 4.5 mg and 5 mg. Jalleh and colleagues point out that GLP-1 receptor activation can slow emptying even at physiological GLP-1 levels, so a low dose should not be assumed to have no effect on the stomach.

Two features of the research favour a gentler experience on a slow, low-dose plan. Tachyphylaxis means the body adapts with continued exposure, and the strongest delay shows up after a first dose or a step-up. A protocol that climbs in small steps may give the stomach more time to adapt at each stage, though that idea has not been tested in a trial.

Slower movement further down the gut is a related but separate issue, covered in our article on constipation on a GLP-1 microdose. Nausea management is covered in managing nausea on a GLP-1 microdose.

Which stomach symptoms on a GLP-1 need a clinician?

Stomach symptoms that keep getting worse, or that do not settle after the first weeks at a stable dose, need a clinician. Repeated vomiting, vomiting food eaten many hours earlier, being unable to keep fluids down, severe or constant abdominal pain, a swollen abdomen, or not passing stool or gas are reasons to seek care promptly rather than wait.

People who already have gastroparesis need a clinician before starting at any dose. The US prescribing information for both Zepbound (tirzepatide) and Wegovy (semaglutide) warns that use has been associated with gastrointestinal adverse reactions, sometimes severe, and states that the drug is not recommended in patients with severe gastroparesis. The Jalleh observation that GLP-1 activation has a limited effect on emptying in people who already empty slowly describes a measurement. It does not show these medicines are safe for people with pre-existing gastroparesis.

Jalleh and colleagues note that slowed gut motility can occasionally contribute to more serious problems such as bowel obstruction, and that well-justified guidance on holding these medicines is limited by thin evidence. A clinician can check for a blockage, review the dose and decide whether a gastric emptying study makes sense.

Frequently asked questions

Clinical references

1. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011. doi:10.2337/db10-0474
2. Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes, Obesity and Metabolism. 2020. doi:10.1111/dom.14110
3. Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021. doi:10.1111/dom.14280
4. Hjerpsted JB, Flint A, Brooks A, et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2018. doi:10.1111/dom.13120
5. Hiramoto B, McCarty TR, Lodhia NA, et al. Quantified metrics of gastric emptying delay by glucagon-like peptide-1 agonists: a systematic review and meta-analysis with insights for periprocedural management. American Journal of Gastroenterology. 2024. doi:10.14309/ajg.0000000000002820
6. Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. Journal of Clinical Endocrinology and Metabolism. 2024. doi:10.1210/clinem/dgae719
7. Aneke-Nash C, Hung KS, Wall-Wieler E, et al. Comparing the risk of gastroparesis following different modalities for treating obesity: semaglutide versus bupropion-naltrexone versus sleeve gastrectomy. BMJ Open Gastroenterology. 2025. doi:10.1136/bmjgast-2024-001704
8. Crisafulli S, Alkabbani W, Paik JM, et al. Comparative gastrointestinal safety of dulaglutide, semaglutide, and tirzepatide in adults with type 2 diabetes. Annals of Internal Medicine. 2026. doi:10.7326/ANNALS-25-01724
9. Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis. Gastrointestinal Endoscopy. 2025. doi:10.1016/j.gie.2024.12.019
10. Elkin J, Rele S, Sumithran P, et al. Association between glucagon-like peptide-1 receptor agonist use and peri-operative pulmonary aspiration: a systematic review and meta-analysis. Anaesthesia. 2025. doi:10.1111/anae.16601
11. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed. 2026. dailymed.nlm.nih.gov
12. Novo Nordisk. WEGOVY (semaglutide) injection, prescribing information. DailyMed. 2026. dailymed.nlm.nih.gov